Registered outcomes17

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 17 of 17

List	Outcome	Time frame	Description
Primary	Number of Participants Classified Based on Education	Baseline; from available retrospective data evaluated during 2 months of this study	Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date.
Primary	Number of Participants Classified Based on Employment Status	Baseline; from available retrospective data evaluated during 2 months of this study	Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date.
Primary	Height	Baseline; from available retrospective data evaluated during 2 months of this study	Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date.
Primary	Weight	Baseline; from available retrospective data evaluated during 2 months of this study	Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date.
Primary	Body Mass Index (BMI)	Baseline; from available retrospective data evaluated during 2 months of this study	Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date.
Primary	Number of Participants Classified Based on Smoking Status	Baseline; from available retrospective data evaluated during 2 months of this study	Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date.
Primary	Number of Participants With at Least 1 Pre-existing Comorbidities	Baseline; from available retrospective data evaluated during 2 months of this study	Pre-existing comorbidities included: asthma, emphysema, chronic obstructive pulmonary disease (COPD), hypertension, diabetes, obesity, cerebrovascular disease, neurological disease, chronic kidney disease, chronic liver disease, malignancy. Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date.
Primary	Number of Participants Who Took at Least 1 Concomitant Medications for Pre-existing Comorbidities	Baseline; from available retrospective data evaluated during 2 months of this study	Baseline was defined as one year before the index date. Index date was Paxlovid prescription written date or dispense date; if neither of them were available, the COVID-19 diagnosis date was used as the index date.
Primary	Number of Participants Who Used Antibiotics	Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study
Secondary	Number of Participants With Hospitalization for Any Cause	Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study
Secondary	Number of Participants With Intensive Care Unit (ICU) Admission for Any Cause	Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study
Secondary	Number of Participants Classified According to Length of Stay (LOS) in ICU for Any Cause	Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study
Secondary	Number of Participants With Yes/no Questionnaire on Outpatient Visits	Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study
Secondary	Number of Participants With Emergency Room (ER) Visits for Any Cause	Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study
Secondary	Number of Participants With Supplemental Oxygen Usage	Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study
Secondary	Number of Participants With Vasopressor Use	Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study
Secondary	Number of Participants Who Used Invasive Mechanical Ventilation (IMV)	Up to 24 months following COVID-19 diagnosis; from available retrospective data evaluated during 2 months of this study

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT06291831/registered

API reference For AI assistants